BACKGROUND: Neutrophil extracellular traps (NETs) can stimulate thrombosis, and their degradation is decreased in several autoimmune disorders. It was recently reported that some patients with haemolytic uraemic syndrome (HUS) also fail to degrade NETs and that neutrophils from Shiga toxin-associated HUS are primed to form NETs. METHOD: We used a well-characterized cohort of 74 thrombotic microangiopathy (TMA) patients, with a subset also providing follow-up samples, and 112 age-matched controls to investigate NET degradation and serum nuclease activity in TMA before, during and after treatment. RESULTS: We identified that in the cohort of TMA patients, 50% of patients with Shiga toxin-associated HUS displayed a decreased ability to degrade NETs. NET degradation correlated with serum nuclease activity, but not with autoantibodies against double-stranded DNA, which has been previously observed in some autoimmune disorders. Further, NET degradation negatively correlated with serum creatinine levels, suggesting that kidney function was negatively impacted by the low NET degradation ability. CONCLUSIONS: We revealed that decreased NET degradation is a common feature of Shiga toxin-associated HUS and that it is associated with decreased kidney function in these patients. It remains to be clarified whether improving NET degradation would be beneficial for the patient.
BACKGROUND: Neutrophil extracellular traps (NETs) can stimulate thrombosis, and their degradation is decreased in several autoimmune disorders. It was recently reported that some patients with haemolytic uraemic syndrome (HUS) also fail to degrade NETs and that neutrophils from Shiga toxin-associated HUS are primed to form NETs. METHOD: We used a well-characterized cohort of 74 thrombotic microangiopathy (TMA) patients, with a subset also providing follow-up samples, and 112 age-matched controls to investigate NET degradation and serum nuclease activity in TMA before, during and after treatment. RESULTS: We identified that in the cohort of TMApatients, 50% of patients with Shiga toxin-associated HUS displayed a decreased ability to degrade NETs. NET degradation correlated with serum nuclease activity, but not with autoantibodies against double-stranded DNA, which has been previously observed in some autoimmune disorders. Further, NET degradation negatively correlated with serum creatinine levels, suggesting that kidney function was negatively impacted by the low NET degradation ability. CONCLUSIONS: We revealed that decreased NET degradation is a common feature of Shiga toxin-associated HUS and that it is associated with decreased kidney function in these patients. It remains to be clarified whether improving NET degradation would be beneficial for the patient.
Authors: Stephen R Clark; Adrienne C Ma; Samantha A Tavener; Braedon McDonald; Zahra Goodarzi; Margaret M Kelly; Kamala D Patel; Subhadeep Chakrabarti; Erin McAvoy; Gary D Sinclair; Elizabeth M Keys; Emma Allen-Vercoe; Rebekah Devinney; Christopher J Doig; Francis H Y Green; Paul Kubes Journal: Nat Med Date: 2007-03-25 Impact factor: 53.440
Authors: Abdul Hakkim; Barbara G Fürnrohr; Kerstin Amann; Britta Laube; Ulrike Abu Abed; Volker Brinkmann; Martin Herrmann; Reinhard E Voll; Arturo Zychlinsky Journal: Proc Natl Acad Sci U S A Date: 2010-05-03 Impact factor: 11.205
Authors: Eneida Villanueva; Srilakshmi Yalavarthi; Celine C Berthier; Jeffrey B Hodgin; Ritika Khandpur; Andrew M Lin; Cory J Rubin; Wenpu Zhao; Stephen H Olsen; Matthew Klinker; David Shealy; Michael F Denny; Joel Plumas; Laurence Chaperot; Matthias Kretzler; Allen T Bruce; Mariana J Kaplan Journal: J Immunol Date: 2011-05-25 Impact factor: 5.422
Authors: Sophie Dennhardt; Wiebke Pirschel; Bianka Wissuwa; Christoph Daniel; Florian Gunzer; Sandro Lindig; Anna Medyukhina; Michael Kiehntopf; Wolfram W Rudolph; Peter F Zipfel; Matthias Gunzer; Marc Thilo Figge; Kerstin Amann; Sina M Coldewey Journal: Front Immunol Date: 2018-06-25 Impact factor: 7.561
Authors: Frederik Denorme; Irina Portier; John L Rustad; Mark J Cody; Claudia V de Araujo; Chieko Hoki; Matthew D Alexander; Ramesh Grandhi; Mitchell R Dyer; Matthew D Neal; Jennifer J Majersik; Christian C Yost; Robert A Campbell Journal: J Clin Invest Date: 2022-05-16 Impact factor: 19.456
Authors: Wouter J C Feitz; Samuel Suntharalingham; Meraj Khan; Carolina G Ortiz-Sandoval; Nades Palaniyar; Lambert P van den Heuvel; Nicole C A J van de Kar; Christoph Licht Journal: Biomedicines Date: 2021-12-01